乳腺癌保留乳头乳晕改良根治术的临床应用价值

doi:10.3760/cma.j.issn.1673-422X.2014.11.020

摘要/Abstract

摘要： 目的探讨保留乳头乳晕的改良根治术在乳腺癌治疗中的可行性、肿瘤的根治性和美容效果。方法选择初治乳腺癌患者96例，其中保留乳头乳晕的改良根治术（NSM）组共35例，改良根治术(MRM)组共61例。对两组患者术后并发症、外观评价、局部复发及远处转移情况进行比较。结果术后并发症NSM组和MRM组差异无统计学意义（χ2=3.140,P=0.061）；外观评价NSM组优于MRM组（χ2=82.786,P=0.000）；随访48～84个月，平均随访63个月，两组患者均无局部复发，NSM组发生远处转移2例（5.7%），MRM组远处转移3例（4.9%），两组远处转移率差异无统计学意义（χ2=0.029,P= 0.866）。结论保留乳头乳晕的改良根治术可以获得与改良根治术相同的治疗效果，术前患者容易接受，术后美容效果好，值得广泛推广。

关键词: 乳腺肿瘤, 乳房切除术, 改良根治性

Abstract: ObjectiveTo investigate the clinical efficacy, curative effects and cosmetic results of nipplesparing modified radical mastectomy (NSM) in the treatment of breast cancer. MethodsNinetysix patients who received initial therapy in Linyi Cancer Hospital from January 1, 2007 to January 1, 2010 were selected. Among them, 35 patients undergoing NSM were chosen as NSM group, 61 patients undergoing modified radical mastectomy (MRM) were chosen as MRM group. The postoperative complications, aesthetic assessment, local recurrence and distant metastasis of the two groups were compared. ResultsIn postoperative complications, the difference of the two groups had no statistical significance (χ2=3.140, P=0.061). NSM group was better than MRM group in aesthetic evaluation (χ2=82.786, P=0.000). Followup was obtained in all patients with range of 48 to 84 months and 63 months in average. Neither of them had local recurrence. Two patients(5.7%) in NSM group and three patients(4.9%) in MRM group developed distant metastasis. The incidents of distant metastasis had no statistically significant difference (χ2=0.029, P=0.866). ConclusionNSM can obtain the same therapeutic effect as MRM, and is easily accepted by patients before operation and has the better aesthetic assessment after operation. NSM is worth spreading widely.

Key words: Breast neoplasms, Mastectomy, modified radical

孔令禹, 苏传付. 乳腺癌保留乳头乳晕改良根治术的临床应用价值[J]. 国际肿瘤学杂志, 2014, 41(11): 866-869.

KONG Ling-Yu, SU Chuan-Fu. Clinical application value of nipple-sparing mastectomy in breast cancer[J]. Journal of International Oncology, 2014, 41(11): 866-869.

参考文献

［1］张保宁, 邵志敏, 乔新民, 等. 中国乳腺癌保乳治疗的前瞻性多中心研究［J］. 中华肿瘤杂志, 2005, 27(11):680684. ［2］ Deutsch M, Land SR, Begovic M, et al. The incidence of lung carcinoma after surgery for breast carcinoma with and without postoperative radiotherapy. Results of National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trials B04 and B06［J］. Cancer, 2003, 98(7):13621368. ［3］ BlichertToft M, Nielsen M, Düring M, et al. Longterm results of breast conserving surgery vs. mastectomy for early stage invasive breast cancer: 20year followup of the Danish randomized DBCG82TM protocol［J］. Acta Oncol, 2008, 47(4):672681. ［4］ Litière S, Werutsky G, Fentiman IS, et al. Breast conserving therapy versus mastectomy for stage ⅠⅡ breast cancer: 20 year followup of the EORTC 10801 phase 3 randomised trial［J］. Lancet Oncol, 2012, 13(4):412419. ［5］ Eriksen C, Frisell J,Wickman M,et al.Immediate reconstruction with implants in women with invasive breast cancer does not affect oncological safety in a matched cohort study［J］. Breast Cancer Res Treat, 2011, 127(2):439446. ［6］左文述, 杨莉, 于志勇. 可手术乳腺癌局部外科治疗的临床实践［J］. 中华乳腺病杂志（电子版）, 2012, 6(1):18. ［7］ Isern AE, Manjer J, Malina J, et al. Risk of recurrence following delayed large flap reconstruction after mastectomy for breast cancer［J］. Br J Surg, 2011, 98(5):659666.

[1]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[2]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[3]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[4]	陈波光, 王苏贵, 张永杰. 血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.
[5]	顾花艳, 朱腾, 郭贵龙. 乳房微生物群与乳腺癌：现状与未来[J]. 国际肿瘤学杂志, 2024, 51(1): 55-58.
[6]	王景, 许文婷. 中性粒细胞与淋巴细胞比值、癌胚抗原联合凝血指标对直径≤1.0 cm的良恶性乳腺结节鉴别诊断价值研究[J]. 国际肿瘤学杂志, 2023, 50(9): 520-526.
[7]	冯诚天, 黄芙蓉, 曹世玉, 王健宇, 南丁阿比雅思, 姜永冬, 朱娟英. HER2阳性乳腺癌患者HER2表达水平与影像学特征的关系[J]. 国际肿瘤学杂志, 2023, 50(9): 527-531.
[8]	冯东旭, 吴炜, 高平发, 王军, 施丽娟, 陈大伟, 李文兵, 张美峰. miR-451通过调控Rho/ROCK1信号通路对乳腺癌细胞糖酵解及凋亡的影响[J]. 国际肿瘤学杂志, 2023, 50(8): 449-456.
[9]	王文德, 曾德. 乳腺癌内分泌治疗耐药的机制研究进展[J]. 国际肿瘤学杂志, 2023, 50(6): 352-356.
[10]	李青珊, 谢鑫, 张楠, 刘帅. 放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[11]	朱军, 黄美金, 李媛, 刘泽刚, 荀欣, 陈宏. HER2低表达乳腺癌的靶向治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 236-240.
[12]	周婷, 徐少华, 梅林. 贝伐珠单抗联合卡培他滨治疗晚期乳腺癌的有效性及安全性[J]. 国际肿瘤学杂志, 2023, 50(3): 144-149.
[13]	黎立喜, 张娣, 罗扬, 马飞. PARP抑制剂在乳腺癌中的临床应用[J]. 国际肿瘤学杂志, 2023, 50(2): 91-96.
[14]	陈群响, 张晓钰, 张妍, 张凯翔, 李捷, 陈曦. 伊尼妥单抗联合长春瑞滨治疗HER2阳性转移性乳腺癌1例[J]. 国际肿瘤学杂志, 2023, 50(12): 763-765.
[15]	耿睿, 马俊强, 郭强, 牛钊峰. 老年乳腺癌患者的综合治疗方式选择倾向及其影响因素[J]. 国际肿瘤学杂志, 2023, 50(11): 650-654.